Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660582 | 1.00 | HRH3 (0.40) | HRH3KCNH2CYP3A4CYP2C9LMNA | |
| SCHEMBL4293472 | 0.86 | HRH3 (0.49) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4293467 | 0.86 | HRH3 (0.49) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4293480 | 0.86 | HRH3 (0.49) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL13660578 | 0.85 | HRH3 (0.57) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL13660585 | 0.84 | HRH3 (0.56) | HRH3KCNH2CYP3A4CYP2C9LMNA | |
| SCHEMBL13660583 | 0.83 | HRH3 (0.62) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4295485 | 0.83 | HRH3 (0.62) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4288776 | 0.82 | PSMB1 (0.56) | HRH3KCNH2CYP3A4CYP2C9KDM4E | |
| SCHEMBL13660576 | 0.82 | PSMB1 (0.56) | HRH3KCNH2CYP3A4CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD | 2005-12-29 | — | — | US | disclosed |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD (US) | 2004-08-26 | — | — | US | disclosed |
| EP-1326863-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002024695-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | HRH3 7/4885KCNH2 488/4885CYP3A4 448/4885 |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | HRH3 7/4885KCNH2 488/4885CYP3A4 448/4885 |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | HRH3 7/4885KCNH2 488/4885CYP3A4 448/4885 |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | HRH3 7/4885KCNH2 470/4885CYP3A4 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.